BACKGROUND: The German Mammography Screening Program (German MSP) is population-based and intended for women aged 50-69 years (approximately 10.5 million). The program started in 2005 and was implemented within 5 years. This article describes the implementation, structure, and screening process, and presents the results of initial examinations for the prevalence phase. METHODS: Data were collected annually from invitation centers (invitation, attendance), screening units (performance, outcomes), and cancer registries (incidence). RESULTS: In 2009, 92% of all annually eligible women were invited; 50% of the annually eligible population participated. The total cancer detection rate in the period of 2005-2009 was 8.1/1,000; the corresponding recall rate was 5.9%. 19.6% of detected cancers were ductal carcinoma in situ; 76.7% of invasive cancers were ≤ 20 mm in size, 30.2% were ≤ 10 mm, and 75.3% were node-negative. During the implementation period, incidence increased by 37 and 56% in the old and new federal states, respectively. Incidence rates decreased following the prevalence phase. CONCLUSION: The German MSP was successfully implemented. The results of the prevalence phase meet the target values of the European guidelines. Proper functioning of the program is also verified by its effects on breast cancer incidence. To draw reliable conclusions regarding the long-term effects of the program, results from the routine screening rounds have to be awaited.
BACKGROUND: The German Mammography Screening Program (German MSP) is population-based and intended for women aged 50-69 years (approximately 10.5 million). The program started in 2005 and was implemented within 5 years. This article describes the implementation, structure, and screening process, and presents the results of initial examinations for the prevalence phase. METHODS: Data were collected annually from invitation centers (invitation, attendance), screening units (performance, outcomes), and cancer registries (incidence). RESULTS: In 2009, 92% of all annually eligible women were invited; 50% of the annually eligible population participated. The total cancer detection rate in the period of 2005-2009 was 8.1/1,000; the corresponding recall rate was 5.9%. 19.6% of detected cancers were ductal carcinoma in situ; 76.7% of invasive cancers were ≤ 20 mm in size, 30.2% were ≤ 10 mm, and 75.3% were node-negative. During the implementation period, incidence increased by 37 and 56% in the old and new federal states, respectively. Incidence rates decreased following the prevalence phase. CONCLUSION: The German MSP was successfully implemented. The results of the prevalence phase meet the target values of the European guidelines. Proper functioning of the program is also verified by its effects on breast cancer incidence. To draw reliable conclusions regarding the long-term effects of the program, results from the routine screening rounds have to be awaited.
Entities:
Keywords:
Breast cancer; Germany; Implementation; Mammography; Screening
Authors: Donella Puliti; Stephen W Duffy; Guido Miccinesi; Harry de Koning; Elsebeth Lynge; Marco Zappa; Eugenio Paci Journal: J Med Screen Date: 2012 Impact factor: 2.136
Authors: Bettina Braun; Laura Khil; Joke Tio; Barbara Krause-Bergmann; Andrea Fuhs; Oliver Heidinger; Hans-Werner Hense Journal: Dtsch Arztebl Int Date: 2018-08-06 Impact factor: 5.594
Authors: Ingo Langner; Christoph Ohlmeier; Ulrike Haug; Hans Werner Hense; Jonas Czwikla; Hajo Zeeb Journal: BMJ Open Date: 2019-07-26 Impact factor: 2.692
Authors: Stefanie Weigel; Joachim Gerss; Hans-Werner Hense; Miriam Krischke; Alexander Sommer; Jörg Czwoydzinski; Horst Lenzen; Laura Kerschke; Karin Spieker; Stefanie Dickmaenken; Sonja Baier; Marc Urban; Gerold Hecht; Oliver Heidinger; Joachim Kieschke; Walter Heindel Journal: BMJ Open Date: 2018-05-14 Impact factor: 2.692